drugset / Trial / NCT01300611

TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation

NCT01300611

Non-randomizedSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant. The study will also evaluate the effect of TXA127 on chemotherapy-induced mucositis, an inflammation of the mucous membranes in the digestive tract (mouth to anus) and immune reconstitution which helps patients fight infections. For patients undergoing CBT, both neutrophil and platelet normalization and immune reconstitution can be delayed. TXA127 has shown to be well tolerated by patients and appears to induce a rapid production of neutrophils and platelets in the bloodstream as well as increase the immune system components. It has also been shown to reduce the severity of chemotherapy-induced mucositis.

Timeline

Start
2011-01
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject talfirastide Peptide 300 ug/kg Other
Subject talfirastide Peptide 1000 ug/kg Other